ArticleJournal of arrhythmia2025
Feasibility of Hybriding Very High-Power Short-Duration and Ablation Index-Guided Pulmonary Vein Isolation.
Article in Journal of arrhythmia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A novel temperature-controlled radiofrequency (RF) catheter enables pulmonary vein isolation (PVI) using very high-power short-duration (vHPSD) ablation, reducing esophageal injury risk but raising concerns about lesion durability in thicker atrial myocardium. This study aimed to assess the efficacy and safety of a hybrid approach that integrates conventional Ablation Index (AI)-guided PVI with vHPSD ablation. Methods: This prospective, single-center study enrolled 160 consecutive patients with atrial fibrillation (AF) between January 2023 and December 2023, who were allocated into two groups. Group 1 ( Results: Group 2 demonstrated a significantly shorter duration for PVI compared to Group 1 (28 ± 11 min vs. 35 ± 10 min, Conclusion: The integration of Ablation Index-guided ablation with vHPSD ablation, utilizing a novel temperature-controlled RF catheter, significantly reduces procedural duration while maintaining safety and efficacy comparable to conventional AI-guided PVI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.